Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD‐L1
Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) remains fatal and incurable, despite a variety of treatments that can delay disease progression and prolong life. Immune checkpoint therapy is a promising treatment. However, emerging evidence suggests that exosomal programm...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2023-08-01
|
| Colección: | Cancer Medicine |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/cam4.6275 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|